CD8A and neoplasm: In summary, YD promotes tumor regression by reducing systemic Treg cells and enhancing the differentiation of peripheral CD8+ T cells into Tcm cells, which subsequently develop into highly effective cytotoxic CD8+ T cells within the tumor microenvironment.